Azurity Pharmaceuticals completed the acquisition of Slayback Pharma from KKR and Everstone.

Azurity Pharmaceuticals, a privately-held pharmaceutical, completed the acquisition of Slayback Pharma, a New Jersey-based company focused on complex generic and specialty pharmaceutical products, from KKR and Everstone, two private equity firms. Financial terms were not disclosed. "I am delighted to announce this combination and the increased potential it brings to do more for overlooked patients. The complementary expertise of the two companies in developing innovative dose forms will result in a strong pipeline of new medicines to meet the needs of patients. We will bring the commercial expertise of Azurity to Slayback's pipeline and look forward to introducing an even wider range of dose-forms and formulations to meet a broader set of patient needs," Richard Blackburn, Azurity CEO.